Certara (NASDAQ:CERT) Shares Down 7% – Time to Sell?

Certara, Inc. (NASDAQ:CERT)’s stock price traded down 7% during trading on Wednesday . The company traded as low as $6.65 and last traded at $6.6650. 1,767,528 shares traded hands during trading, a decline of 52% from the average session volume of 3,701,465 shares. The stock had previously closed at $7.17.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CERT. Robert W. Baird decreased their target price on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 12th. BMO Capital Markets cut their price objective on Certara from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. Barclays reduced their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Finally, KeyCorp decreased their price target on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.85.

Certara Stock Performance

The firm has a fifty day moving average price of $5.66 and a 200 day moving average price of $6.82. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.28. The firm has a market cap of $1.04 billion, a PE ratio of -66.75 and a beta of 1.46.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The firm had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. The company’s revenue for the quarter was up .8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities research analysts expect that Certara, Inc. will post 0.24 earnings per share for the current fiscal year.

Institutional Trading of Certara

Several institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC acquired a new stake in shares of Certara in the first quarter valued at $259,000. Goldman Sachs Group Inc. lifted its stake in Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after purchasing an additional 90,724 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Certara by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after purchasing an additional 35,954 shares in the last quarter. Jane Street Group LLC raised its holdings in Certara by 17.1% during the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Certara by 29.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after buying an additional 21,099 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.